Castle Biosciences, Inc.
Castle Biosciences, Inc., a leading biotechnology company headquartered in the United States, specialises in innovative diagnostic solutions for skin cancer and other complex diseases. Founded in 2007, the company has made significant strides in the field of personalised medicine, particularly with its flagship products, the DecisionDx® tests, which provide critical insights for melanoma and non-melanoma skin cancers. With a strong presence across the US and expanding operations internationally, Castle Biosciences is recognised for its commitment to improving patient outcomes through advanced genomic testing. The company has achieved notable milestones, including the successful launch of its proprietary tests that help clinicians make informed treatment decisions. As a pioneer in the dermatological diagnostics industry, Castle Biosciences continues to set the standard for precision medicine, solidifying its position as a trusted partner in oncology care.
DitchCarbon Score
How does Castle Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Castle Biosciences, Inc.'s score of 25 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Castle Biosciences, Inc.'s reported carbon emissions
Castle Biosciences, Inc., headquartered in the US, currently does not have available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. As a result, Castle Biosciences has not publicly committed to any specific climate initiatives or reduction strategies at this time. The lack of emissions data and reduction commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. In the context of the industry, many organisations are increasingly focusing on sustainability and carbon footprint reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific data or commitments from Castle Biosciences, it is unclear how they plan to address their carbon emissions in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Castle Biosciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
